https://www.selleckchem.com/products/mln-4924.html After a median follow-up of 3 years for survivors, 21 patients were alive, 19 of whom were event free, while 2 patients died of disease recurrence and 1 died of treatment-related myelodysplastic syndrome. The 3-year overall, lymphoma relapse-free, and event-free survival rates were 86%, 86%, and 82%, respectively. Taking into consideration the poor-risk features of the study cohort, IFRT provided early after autologous hematopoietic stem-cell transplantation showed a safe and well-tolerated toxicity profile and demonstrated long-term effective tumor control, as reflected in the promising survival rates. Taking into consideration the poor-risk features of the study cohort, IFRT provided early after autologous hematopoietic stem-cell transplantation showed a safe and well-tolerated toxicity profile and demonstrated long-term effective tumor control, as reflected in the promising survival rates. The role of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for children with intermediate-risk acute myeloid leukemia (IR-AML) in first complete remission has been controversial. The present study compared the effect of chemotherapy with unmanipulated haplo-HSCT as treatment of patients with IR-AML in first complete remission (CR1). We retrospectively analyzed the outcomes of 80 children with IR-AML and compared the effects of chemotherapy (n= 47) with those of haplo-HSCT (n= 33) as treatment in CR1. The 3-year overall survival, event-free survival (EFS), and cumulative incidence of relapse (CIR) was 85.4% ±4.1%, 73.2% ± 5.0%, and 25.4% ± 4.5%, respectively. Compared with the chemotherapy group, the patients in the haplo-HSCT group had a lower CIR (P= .059) and better EFS (P= .108), but roughly equivalent overall survival (P=.841). Multivariate analysis revealed chemotherapy and minimal residual disease (MRD) of≥ 10 after induction therapy as independent risk factors affecting CIR and EFS. EFS (P= .045) and